Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Brimonidine, latanoprost, tralokinumab, dupilumab, and allopurinol may increase the risk of conjunctivitis, research suggests.

Sanofi to showcases leadership and breadth of scientific innovation in chronic inflammatory respiratory conditions at ATS conference: Paris Saturday, May 3, 2025, 16:00 Hrs [IST] ...

Tofacitinib, a Janus kinase (JAK) inhibitor drug, used either as a standalone treatment or alongside other drugs to address ...